Mesalamine 4 gm/60 mL Rectal Enema
A Study to Evaluate the Relative Bioavailability of Two Mesalamine 4 gm/60 mL Rectal Enema Formulations
Sponsor study identifier
interventional
72
1 country
1
Study Start
May 2003
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2003
Actual (reported)Study Completion
June 2003
Actual (reported)The objective of this study is to evaluate the relative bioavailability of the test formulation of mesalamine suspension rectal enema with the already marketed reference formulation Rowasa® in healthy, adult subjects.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2003
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 2003
Date type not reportedThis date has not been verified as actual or estimated.
June 2003
Actual (reported)June 2003
Actual (reported)February 6, 2009
Actual (reported)February 10, 2009
Actual (reported)August 4, 2009
Actual (reported)Cmax - Maximum Observed Concentration
Bioequivalence based on Cmax
Blood samples collected over 48 hour period
AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
Bioequivalence based on AUC0-inf
Blood samples collected over 48 hour period
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
Bioequivalence based on AUC0-t
Blood samples collected over 48 hour period
Cmax - Maximum Observed Concentration
Blood samples collected over 48 hour period
AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
Blood samples collected over 48 hour period
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
Blood samples collected over 48 hour period
Mesalamine 4gm/60mL Rectal Enema (test) dosed in first period followed by Rowasa® 4gm/60mL Rectal Enema (reference) dosed in second period
Rowasa® 4gm/60mL Rectal Enema (reference) dosed in first period followed by Mesalamine 4gm/60mL Rectal Enema (test) dosed in second period
1 x 4 gm/60 mL, single-dose
1 x 4 gm/60 mL, single-dose
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Novum Pharmaceutical Research Services
Pittsburgh, Pennsylvania, 15206, United States
Shirley Ann Kennedy, M.D.
Novum Pharmaceutical Research Services
72 participants (actual enrollment reported by the registry).
First Submitted
February 6, 2009
First Posted
February 10, 2009
Study Start
May 2003
Date type not reportedThis date has not been verified as actual or estimated.
Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions
Contact the study team to confirm eligibility.
Primary Completion
June 2003
Actual (reported)Study Completion
June 2003
Actual (reported)Last Updated
August 19, 2024
Results First Posted
August 4, 2009
Record last verified: 2024-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: